Published in Virchows Arch on November 29, 2005
Cancer biomarker discovery: the entropic hallmark. PLoS One (2010) 1.26
AMACR amplification and overexpression in primary imatinib-naïve gastrointestinal stromal tumors: a driver of cell proliferation indicating adverse prognosis. Oncotarget (2014) 0.90
CD24 expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression. Virchows Arch (2006) 0.81
Alpha-methylacyl-CoA racemase (AMACR) expression in epithelial ovarian cancer. Virchows Arch (2011) 0.79
Sertoli cell tumor of the testis, not otherwise specified, presenting extensive hemorrhage and overexpression of alpha-methylacyl-CoA racemase (AMACR/P504S). Virchows Arch (2007) 0.75
Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med (1998) 25.41
Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology (1998) 3.81
Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst (2003) 3.73
Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. Am J Surg Pathol (2002) 2.10
Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases. Hum Pathol (2003) 2.00
Peroxisomal fatty acid alpha- and beta-oxidation in humans: enzymology, peroxisomal metabolite transporters and peroxisomal diseases. Biochem Soc Trans (2001) 1.52
The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis. Breast Cancer Res Treat (2003) 1.36
alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation. Am J Pathol (2002) 1.34
Subcellular localization and physiological role of alpha-methylacyl-CoA racemase. J Lipid Res (2000) 1.33
Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev (2005) 1.33
Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature. Histopathology (2005) 1.25
Value of CDX2, villin, and alpha-methylacyl coenzyme A racemase immunostains in the distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Mod Pathol (2005) 1.20
Using an AMACR (P504S)/34betaE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens. Am J Clin Pathol (2005) 1.11
Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer. Cancer Res (2003) 1.09
Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer. BJU Int (2000) 1.09
Discovery and clinical application of a novel prostate cancer marker: alpha-methylacyl CoA racemase (P504S). Am J Clin Pathol (2004) 1.08
Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens. Hum Pathol (2004) 1.07
Alpha-methylacyl CoA racemase (P504S): overview and potential uses in diagnostic pathology as applied to prostate needle biopsies. J Clin Pathol (2003) 1.00
Expression of alpha-methylacyl-CoA racemase in papillary renal cell carcinoma. Am J Surg Pathol (2004) 1.00
A dietary enzyme: alpha-methylacyl-CoA racemase/P504S is overexpressed in colon carcinoma. Cancer Detect Prev (2003) 0.99
Gene expression profiles in prostate cancer: association with patient subgroups and tumour differentiation. Int J Oncol (2005) 0.98
Immunohistochemical stains for p63 and alpha-methylacyl-CoA racemase, versus a cocktail comprising both, in the diagnosis of prostatic carcinoma: a comparison of the immunohistochemical staining of 430 foci in radical prostatectomy and needle biopsy tissues. Am J Surg Pathol (2005) 0.94
The role of alpha-methylacyl-CoA racemase in bile acid synthesis. Biochem J (2002) 0.94
Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder. J Urol (2003) 0.93
P63 immunoreactivity distinguishes upper urinary tract transitional-cell carcinoma and renal-cell carcinoma even in poorly differentiated tumors. J Histochem Cytochem (2003) 0.90
Urothelial neoplasms of the kidney and ureter. An epidemiologic, pathologic, and clinical review. Am J Clin Pathol (2002) 0.84
Expression of genes and proteins specific for prostate cancer. J Urol (2004) 0.83
Alpha-methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis. Cancer Epidemiol Biomarkers Prev (2005) 0.82
Differential expression of alpha-methylacyl coenzyme A racemase in adenocarcinomas of the small and large intestines. Am J Surg Pathol (2005) 0.81
Immunohistochemical detection of P504S in primary and metastatic renal cell carcinomas. Appl Immunohistochem Mol Morphol (2004) 0.81
Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science (2006) 7.35
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol (2013) 6.54
ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-α and PGC-1. Nat Med (2011) 3.96
Adipose triglyceride lipase contributes to cancer-associated cachexia. Science (2011) 3.70
N-terminal pro-brain natriuretic peptide identifies patients at high risk for adverse cardiac outcome after vascular surgery. Anesthesiology (2007) 3.38
Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer (2009) 3.12
European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol (2013) 2.93
External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. Eur Urol (2008) 2.85
European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol (2011) 2.70
Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. Eur Urol (2009) 2.55
The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. Eur Urol (2011) 2.43
Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. Eur Urol (2008) 2.37
Predictive value of seven preoperative prognostic scoring systems for spinal metastases. Eur Spine J (2008) 2.33
Collecting duct renal cell carcinoma: a matched analysis of 41 cases. Eur Urol (2007) 2.30
Assessment of the minimum number of lymph nodes needed to detect lymph node invasion at radical nephroureterectomy in patients with upper tract urothelial cancer. Urology (2009) 2.17
Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol (2012) 2.17
Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival. Eur Urol (2006) 2.15
Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol (2011) 2.10
Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol (2007) 2.09
Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology (2005) 2.00
Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. J Urol (2009) 1.90
Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol (2007) 1.90
The extent of lymphadenectomy seems to be associated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma: how many lymph nodes should be removed? Eur Urol (2009) 1.78
A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur Urol (2008) 1.77
Growth retardation, impaired triacylglycerol catabolism, hepatic steatosis, and lethal skin barrier defect in mice lacking comparative gene identification-58 (CGI-58). J Biol Chem (2009) 1.72
Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors. J Mol Diagn (2009) 1.72
External validation of the Leibovich prognosis score for nonmetastatic clear cell renal cell carcinoma at a single European center applying routine pathology. J Urol (2011) 1.69
Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience. J Urol (2007) 1.67
Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase. Proc Natl Acad Sci U S A (2003) 1.65
Validation of pretreatment neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma. BJU Int (2013) 1.63
Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. Eur Urol (2011) 1.62
Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study. Circ Cardiovasc Interv (2012) 1.61
Incisional hernia following liver transplantation: incidence and predisposing factors. Clin Transplant (2007) 1.58
The impact of previous ureteroscopic tumor ablation on oncologic outcomes after radical nephrouretectomy for upper urinary tract urothelial carcinoma. J Endourol (2011) 1.53
Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol (2009) 1.52
Autologous fibrin glue using the Vivostat system for hemostasis in laparoscopic partial nephrectomy. Eur Urol (2006) 1.52
Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration. BJU Int (2011) 1.50
Persisting eustachian valve in adults: relation to patent foramen ovale and cerebrovascular events. J Am Soc Echocardiogr (2004) 1.46
Keratin 7 expression in colorectal cancer--freak of nature or significant finding? Histopathology (2011) 1.45
Implementation of formalin-fixed, paraffin-embedded cell line pellets as high-quality process controls in quality assessment programs for KRAS mutation analysis. J Mol Diagn (2012) 1.44
A large Eustachian valve is a confounder of contrast but not of color Doppler transesophageal echocardiography in detecting a right-to-left shunt across a patent foramen ovale. Int J Cardiol (2005) 1.44
Oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: comparison over the three decades. Int J Urol (2012) 1.43
Translational regulation mechanisms of AP-1 proteins. Mutat Res (2009) 1.42
Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. J Urol (2010) 1.40
Aminoterminal pro-B-type natriuretic peptide: heart or lung disease in the neonate?. Pediatr Crit Care Med (2013) 1.40
Hyperhomocyst(e)inemia and Chlamydia pneumoniae IgG seropositivity in patients with coronary artery disease. Atherosclerosis (2002) 1.39
A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell (2013) 1.37
Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia. J Lipid Res (2008) 1.36
Adipose triglyceride lipase plays a key role in the supply of the working muscle with fatty acids. J Lipid Res (2009) 1.36
Tumor necrosis is a new promising prognostic factor in colorectal cancer. Hum Pathol (2010) 1.34
Relationship between age at diagnosis and clinicopathologic features of renal cell carcinoma. Eur Urol (2006) 1.27
Intramural and extramural vascular invasion in colorectal cancer: prognostic significance and quality of pathology reporting. Cancer (2011) 1.26
Common alterations in gene expression and increased proliferation in recurrent acute myeloid leukemia. Oncogene (2004) 1.26
External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients. PLoS One (2013) 1.23
Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol (2012) 1.21
Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. Eur Urol (2009) 1.21
The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling. Blood (2007) 1.18
Accuracy of life tables in predicting overall survival in patients after radical prostatectomy. BJU Int (2008) 1.18
miR-192, miR-194, miR-215, miR-200c and miR-141 are downregulated and their common target ACVR2B is strongly expressed in renal childhood neoplasms. Carcinogenesis (2012) 1.17
Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer. BJU Int (2008) 1.11
Prognostic ability of simplified nuclear grading of renal cell carcinoma. Cancer (2007) 1.11
Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol (2012) 1.10
Sustained PU.1 levels balance cell-cycle regulators to prevent exhaustion of adult hematopoietic stem cells. Mol Cell (2013) 1.09
Tumor budding is an independent predictor of outcome in AJCC/UICC stage II colorectal cancer. Ann Surg Oncol (2012) 1.08
Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia. Cancer Res (2006) 1.08
The effect of a single infusion of zoledronic acid on early implant migration in total hip arthroplasty. A randomized, double-blind, controlled trial. J Bone Joint Surg Am (2009) 1.08
Molecular cytogenetics and multiplex reverse-transcriptase polymerase chain reaction for risk stratification in acute myeloid leukemia. J Clin Oncol (2013) 1.07
Bladder tumour development after urothelial carcinoma of the upper urinary tract is related to primary tumour location. BJU Int (2006) 1.05
Steroid hormone receptor expression in renal cell carcinoma: an immunohistochemical analysis of 182 tumors. J Urol (2004) 1.05
Expression of MUC1 (EMA) and E-cadherin in renal cell carcinoma: a systematic immunohistochemical analysis of 188 cases. Mod Pathol (2004) 1.05
Report of an international survey of molecular genetic testing laboratories. Community Genet (2007) 1.04
Age at diagnosis is a determinant factor of renal cell carcinoma-specific survival in patients treated with nephrectomy. Can Urol Assoc J (2008) 1.03
Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. BJU Int (2008) 1.03
Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma. Urology (2004) 1.03
Keratin immunohistochemistry in renal cell carcinoma subtypes and renal oncocytomas: a systematic analysis of 233 tumors. Virchows Arch (2004) 1.02
Conditional survival predictions after nephrectomy for renal cell carcinoma. J Urol (2009) 1.02
Biologic significance of fascin expression in clear cell renal cell carcinoma: systematic analysis of primary and metastatic tumor tissues using a tissue microarray technique. Urology (2006) 1.02
Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group. Eur Urol (2006) 1.02
Defective DNA-mismatch repair: a potential mediator of leukemogenic susceptibility in therapy-related myelodysplasia and leukemia. Genes Chromosomes Cancer (2002) 1.01
Analysis of insulin-like growth factors and insulin-like growth factor I receptor expression in renal cell carcinoma. Am J Clin Pathol (2004) 0.99
Risk stratification of patients with nodal involvement in upper tract urothelial carcinoma: value of lymph-node density. BJU Int (2008) 0.99
miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor. J Clin Pathol (2013) 0.99
Role of adipose triglyceride lipase (PNPLA2) in protection from hepatic inflammation in mouse models of steatohepatitis and endotoxemia. Hepatology (2014) 0.99
Impact of tumor-associated symptoms on the prognosis of patients with renal cell carcinoma: a single-center experience of 683 patients. Urology (2003) 0.98
Adipose triglyceride lipase is a TG hydrolase of the small intestine and regulates intestinal PPARα signaling. J Lipid Res (2012) 0.98